Skip to content
shutterstock_651722116 shutterstock_651722116

Quanterix® SIMOA™ Assays

For clinical development programs that need biomarker detection with high sensitivity and broad dynamic range, Precision uses the Quanterix SIMOA platform.
The SIMOA SR-X platform can deliver 1000-fold higher sensitivity than traditional ELISAs, yielding analyte detection in the femtomolar (fM) range and enabling analysis of previously difficult or even impossible-to-quantify biomarkers, such as CNS-specific or -derived biomarkers in serum and plasma as well as ultrasensitive PK assays for early dose escalation trials. Additionally, high sensitivity detection allows for the discovery of new biomarkers, creating opportunities for the development of novel diagnostics and companion diagnostics.

Precision offers ultra-sensitive biomarker detection using Quanterix SIMOA

Advancing biomarker-driven research through femtomolar detection and quantification of low abundance or challenging biomarkers

Example uses of Quanterix SIMOA

  • Biomarker discovery: quantify previously unmeasurable proteins and nucleic acids
  • Uncover Dx and CDx opportunities
  • Protein counting in single cancer cells
  • Measurement of neurology biomarkers in matrices other than CSFm
  • PK/ADA assays (gene therapy)

Sample types analyzed:

  • Plasma
  • Serum
  • CSF
  • Urine
  • Cell extracts

Selection of key biomarkers targets and uses :


  • NfL: neurodegeneration biomarker in multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease and other indications.
  • Tau: Alzheimer's disease, frontotemporal dementia.
  • Aβ42, Aβ40: Alzheimer's disease, frontotemporal dementia.
  • UCHL1, NfL, Tau GFAP: traumatic brain injury, stroke.

Gene therapy

  • AAV antibodies: TAb assays in gene therapy.
  • Transgene products


  • Cytokine panels
  • Inflammatory proteins

Neurology applications of SIMOA technology

Historically, several important neurology biomarkers, including neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (P-NfH) could only be reliably measured in cerebrospinal fluid (CSF). Plasma/serum (or blood) concentrations of these biomarkers are too low for detection using standard ELISA methods.

Utilizing the 1000-fold higher sensitivity of the SIMOA platform, Precision can reliably measure these biomarkers from blood draws, offering significant benefits in neurology studies:

  • Lower patient burden – Sampling CSF can be challenging and is associated with higher patient discomfort and an increased risk of complications. In contrast, blood draws are easier on patients and have a lower risk of complications.
  • Improved longitudinal data – Because blood draws are more accessible, samples may be collected more frequently and in larger volumes than when sampling CSF. This helps build a richer and more informative biomarker data set over time for each patient and across patients.

Gold standard biomarkers in neurology therapeutic development

Discover biomarker approaches specific to neurology therapeutic development, including how SIMOA assays can be used for measurement of CNS-specific biomarkers in blood.


Developing a comprehensive biomarker strategy for neurology therapeutic development

Download Whitepaper
Developing a comprehensive biomarker strategy for neurology therapeutic development

Related services

  • Large Molecule PK

    Development, validation, and implementation using ELISAs and MSD assays for biologics, flow cytometry and ddPCR for cell-based therapies, and Quanterix SIMOA® for ultrasensitive analyte detection
  • Cytokine

    MesoScale Discovery (MSD)

    Measuring a range of analytes in complex sample matrices consistently and at high sensitivity, with applications including ADA, NAb, TAb, and PK assays

    Services using the gold standard for quantitative antibody-based bioanalysis, with specialization in immunogenicity assay development